InflaRx (IFRX) financial statements

Healthcare · Biotechnology · Market cap $229M

InflaRx reported revenue of 29,331 EUR in fiscal 2025, down 31.8% a year over 2 years.

Net income was -46M EUR.

Free cash flow was -35M EUR.

The diluted share count rose 2847480% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions (EUR).

-0.1-0.0-0.000.02016201720182019202020212022202320242025RevenueFree cash flow
Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

Income statement

Fiscal years, in EUR, from InflaRx's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Revenue-7M EUR-19M EUR-38M EUR———-32M EUR63,089 EUR165,789 EUR29,331 EUR
Cost of revenue———————532,262 EUR3M EUR7M EUR
Gross profit-7M EUR-20M EUR-38M EUR————-469,173 EUR-3M EUR-7M EUR
Research and development5M EUR14M EUR25M EUR45M EUR26M EUR36M EUR38M EUR41M EUR35M EUR26M EUR
Selling, general and admin2M EUR5M EUR13M EUR13M EUR8M EUR105,790 EUR97,413 EUR95,205 EUR41,400 EUR15,963 EUR
Operating income—————-48M EUR-32M EUR-45M EUR——
Interest expense2M EUR5M EUR0 EUR0 EUR18,689 EUR10,714 EUR23,303 EUR16,538 EUR885 EUR2,692 EUR
Pre-tax income-9M EUR-24M EUR-30M EUR-53M EUR-34M EUR-46M EUR-29M EUR-43M EUR-46M EUR-46M EUR
Income tax0 EUR0 EUR0 EUR0 EUR0 EUR0 EUR——5,217 EUR12,282 EUR
Net income-9M EUR-24M EUR-30M EUR-53M EUR-34M EUR-46M EUR-29M EUR-43M EUR-46M EUR-46M EUR
EPS (diluted)————-1.26 EUR-1.10 EUR-0.67 EUR-0.78 EUR-0.78 EUR-0.68 EUR
Diluted shares0M9M25M26M27M42M44M55M59M67M
Gross margin103.4%100.6%100.8%————-743.7%-1900.8%-24677.9%
Operating margin——————100.0%-71182.1%——
Net margin129.7%124.6%79.5%———91.5%-67630.7%-27785.0%-155582.1%

Balance sheet

Fiscal years, in EUR, from InflaRx's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Cash and short-term investments29M EUR123M EUR55M EUR33M EUR26M EUR26M EUR16M EUR13M EUR18M EUR16M EUR
Inventory———————11M EUR7M EUR—
Total current assets29M EUR124M EUR158M EUR119M EUR86M EUR96M EUR97M EUR109M EUR72M EUR54M EUR
Property, plant and equipment—173,000 EUR624,668 EUR576,373 EUR408,263 EUR274,373 EUR328,920 EUR289,577 EUR256,280 EUR289,317 EUR
Total assets30M EUR124M EUR159M EUR122M EUR88M EUR125M EUR102M EUR120M EUR76M EUR55M EUR
Total current liabilities2M EUR5M EUR8M EUR14M EUR10M EUR19M EUR13M EUR17M EUR14M EUR13M EUR
Long-term debt—————0 EUR————
Total liabilities55M EUR5M EUR8M EUR14M EUR10M EUR20M EUR14M EUR18M EUR15M EUR14M EUR
Shareholders' equity-26M EUR119M EUR151M EUR107M EUR78M EUR105M EUR7M EUR7M EUR7M EUR7M EUR
Net debt-29M EUR-123M EUR-55M EUR-33M EUR-26M EUR-26M EUR-16M EUR-13M EUR-18M EUR-16M EUR

Cash flow

Fiscal years, in EUR, from InflaRx's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Operating cash flow-5M EUR-12M EUR-22M EUR-43M EUR-37M EUR-40M EUR-34M EUR-38M EUR-49M EUR-35M EUR
Capital spending53,000 EUR148,542 EUR806,531 EUR-594,889 EUR0 EUR0 EUR162,391 EUR81,100 EUR46,871 EUR115,694 EUR
Free cash flow-5M EUR-12M EUR-22M EUR-43M EUR-37M EUR-40M EUR-34M EUR-38M EUR-49M EUR-35M EUR
Stock-based compensation————1M EUR4M EUR6M EUR3M EUR4M EUR4M EUR
Net borrowing—0 EUR0 EUR296,020 EUR-366,156 EUR-360,644 EUR-364,430 EUR-373,977 EUR-388,114 EUR-357,583 EUR
Free cash flow margin73.2%63.3%59.6%———105.2%-60064.5%-29316.5%-120793.8%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IFRX.
Open IFRX in Investingly

Questions

What was InflaRx's revenue in 2025?

29,331 EUR in fiscal 2025, from its 10-K filing.

How much free cash flow does InflaRx generate?

-35M EUR in fiscal 2025 (operating cash flow minus capital spending).

From InflaRx's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.